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In 2009 there were an estimated 2.5 million children under the age 
of 15 years living with HIV worldwide, and 370 000 new infections 
in children, the vast majority due to mother-to-child transmission 
(MTCT) in sub-Saharan Africa.1 Without intervention, MTCT 
of HIV is 25 - 45%.2 Effective counselling and testing, access to 
antiretroviral therapy, and safe delivery and infant feeding practices 
have virtually eliminated MTCT in high-income countries. 
In South Africa in 2009, 29.4% of women aged 15 - 49 years 
attending public health clinics for antenatal care were HIV positive.3 
Although child mortality is falling worldwide, in South Africa it has 
risen,4 and HIV is responsible for 40% of deaths, thereby constituting 
the leading cause of under-5 mortality.5 Roll-out and progress of 
prevention of mother-to-child HIV transmission (PMTCT) services, 
commenced almost a decade ago in South Africa, has been slow.6,7  
PMTCT programmes offer a unique opportunity for health 
services to provide comprehensive treatment and care; engage with 
women living with HIV, their infants and their partners; and establish 
relationships that could improve their long-term survival. Despite 
concerns about subsequent drug resistance,8,9 PMTCT services in 
the public sector in South Africa, as in many resource-constrained 
countries, offered a single dose of nevirapine to the mother and her 
infant at delivery, until early 2008 when dual therapy (zidovudine 
during pregnancy and nevirapine at delivery) was introduced. 
Previously we described the results of the first 18 months of a South 
African PMTCT programme in which dual and triple therapy have 
been used since 2004.10 We now report on outcomes achieved and 
lessons learned in the programme after 3 years. 
Methods
A retrospective cohort study design was used to describe maternal 
and child health outcomes of women who received PMTCT care 
between March 2004 and February 2007 at McCord Hospital, a 
state-aided general hospital in Durban, KwaZulu-Natal (KZN). This 
PMTCT service was supported by the Elizabeth Glaser Pediatric 
AIDS Foundation and the US President’s Emergency Plan for 
AIDS Relief (PEPFAR). It is integrated with routine antenatal care, 
and serves a diverse catchment population. Whereas antenatal 
HIV seroprevalence in the KZN public sector was almost 40%,3 at 
McCord it was 14%. During the study period, patients were charged 
a subsidised user fee of R140 (~$19.26 in 2005 US dollars) for each 
antenatal visit, which included comprehensive PMTCT care. ‘Opt-
out testing’ was adopted in August 2006 using the CDC definition11 
where information regarding a batch of recommended antenatal 
tests is conveyed during a group session and patients are able to opt 
out of any tests. Postnatally, mothers were referred for follow-up at 
the HIV clinic, where the inclusive cost was R160 per visit. Three-
monthly visits were required for women continuing on triple therapy 
(highly active antiretroviral therapy (HAART)) and 6-monthly visits 
for those who received antiretrovirals for PMTCT only. HIV-positive 
babies were followed up at the same HIV clinic, while negative babies 
were referred to government immunisation clinics after the 6-week 
polymerase chain reaction (PCR) test and result.
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Objective. To determine outcomes of pregnant women and their 
infants at McCord Hospital in Durban, South Africa, where dual 
and triple therapy to reduce HIV vertical transmission have been 
used since 2004 despite national guidelines recommending simpler 
regimens. 
Method. We retrospectively examined records of all pregnant 
women attending McCord Hospital for their first antenatal visit 
between 1 March 2004 and 28 February 2007. Uptake of HIV testing 
and HIV prevalence were determined, and clinical, immunological 
and virological outcomes of HIV-positive women and their infants, 
followed through to 6 months after delivery, were described. 
Results. The antenatal clinic was attended by 5 303 women; 
4 891 (92%) had an HIV test, and 703 (14%) were HIV positive. 
The HIV-positive women were subsequently followed up: 653 
(93%) received antiretroviral therapy or prophylaxis, including 424 
(60%) who received triple therapy. Of the 699 live babies delivered, 
661 (94%) received prophylaxis. At 6 weeks 571 babies (82%) were 
brought back for HIV testing; 16 (2.8%) were HIV positive. After 
6 months, only 150 women (21%) were receiving follow-up care at 
the adult HIV clinic. 
Conclusion. Where a tailored approach to prevention of mother-
to-child transmission (PMTCT) is used, which attempts to 
maximise available technology and resources, good short-term 
transmission outcomes can be achieved. However, longer-term 
follow-up of mothers’ and babies’ health presents a challenge. 
Successful strategies to link women to ongoing care are crucial to 
sustain the gains of PMTCT programmes.
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The PMTCT treatment options at McCord were influenced by 
international best practice and evidence12 and did not follow the 
public sector guidelines, which at the time recommended single-dose 
nevirapine at birth for women with CD4 counts >200 cells/μl. Over 
the study period, McCord PMTCT programme clinical guidelines 
evolved as evidence emerged, drugs became more available, and 
funding for dual and triple therapy was secured. The choice of regimen 
for individual women was determined by CD4 count, viral load, 
prior use of antiretroviral therapy, cost factors and the gestational 
age at which women presented for antenatal care (Table I). Initially a 
caesarean section was offered to all women to reduce intrapartum HIV 
transmission. By mid-2005, a routine viral load test at 36 weeks enabled 
a policy of recommending vaginal delivery (if there was no obstetric 
indication for caesarean section) in women with a viral load <1 000 
copies/ml. All infants were to be given a single dose of nevirapine 
within 72 hours of birth and zidovudine for 1 week.
Records of all pregnant women attending McCord Hospital for 
their first antenatal visit between 1 March 2004 and 28 February 
2007 were examined to determine uptake of HIV testing and HIV 
prevalence. Clinical, immunological and virological outcomes of 
HIV-positive women and their infants were followed up to 6 months 
after delivery. Data were analysed using SPSS 15 (SPSS Inc., Chicago, 
Ill). To determine associations between maternal characteristics and 
loss to follow-up at 6 weeks, we conducted bivariate analysis using 
chi-square tests. Chi-square for trend was used to identify change in 
regimen and delivery methods over time. Two-tailed p-values <0.05 
were considered statistically significant. The study was approved 
by the University of KwaZulu-Natal Biomedical Research Ethics 
Committee and the McCord Hospital Research Ethics Committee.
Results
During the 3-year period, 5 303 women attended the McCord 
Hospital antenatal clinic; all received counselling, and 92% (N=4 891) 
accepted HIV testing (Fig. 1). Of the tested women 703 (14%) were 
HIV positive, and 266 (38%) of their partners were tested at McCord 
Hospital of whom 182 (68%) were HIV positive.
Of the 703 HIV-positive women, 653 (93%) received antiretroviral 
therapy; of these, 424 (60%) received triple therapy (Tables II and III). 
From programme year 1 to year 3 the use of triple therapy increased 
from 39% to 71% (χ2trend=48.7, p<0.001), while single-dose nevirapine 
prophylaxis decreased from 32% to 11% (χ2trend=34.9, p<0.001) (Table 
II). Dual therapy declined from 23% in year 1 to 8% in year 2 and 10% 
in year 3. Baseline CD4 counts were performed before antiretroviral 
initiation in 642 (91%) of the HIV-positive cohort, of whom 146 (23%) 
had CD4 counts <200 cells/μl (Table II). Of these 146 HAART-eligible 
women, 122 (84%) were commenced on HAART for life.
Among the 703 HIV-positive women, 700 delivered; of these, 694 
delivered live infants, including 5 pairs of twins (Table II). Of the 680 
births for which the delivery method was documented, 427 (63%) 
were by caesarean section. There was a significant reduction in the 
proportion of deliveries by caesarean section from 74% (154/208) 
in year 1 to 57% (119/210) in year 2 and 59% (154/262) in year 3 
(χ2trend=9.6, p=0.002). 
After delivery, 661 of the 699 (95%) babies received antiretroviral 
prophylaxis: 585 (89%) received a single dose of nevirapine and 1 
week of zidovudine, 68 (10%) received nevirapine only, and 8 (1%) 
received prophylaxis but the regimen was not specified. In 38 babies 
(5%) no prophylaxis was recorded. 
Table I. Changing PMTCT treatment guidelines for HIV-positive pregnant women attending the McCord antenatal clinic, Durban, 
1 March 2004 - 28 February 2007
Time period CD4 <200 cells/µl CD4 ≥200 cells/µl Late presenters*
March 2004 - May 2005 HAART† for life Single-dose nevirapine, dual 
or triple therapy depending on 
woman’s ability to pay
Single-dose nevirapine
June 2005 - February 2007
(funding secured for more 
complex regimens for all women 
to reduce inequity)
HAART for life Viral load (first visit) <1 500 copies/
ml: dual therapy‡ and zidovudine 
and lamivudine tail for 7 days
Viral load ≥1 500 copies/ml: 
triple therapy from 28 weeks 
until birth and zidovudine and 
lamivudine tail for 7 days
Single-dose nevirapine in labour 
with a zidovudine and lamivudine 
tail of 7 days
*After 38 weeks’ gestation. 
†Highly active antiretroviral therapy (actual regimens presented in Table III).
‡Dual therapy, zidovudine during pregnancy and nevirapine at delivery.
Fig. 1. Flow diagram of follow-up of women attending McCord antenatal clinic, Durban, March 
2004 - February 2007. 
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Fig. 1. Flow diagram of follow-up of women attending McCord antenatal 
clinic, Durban, March 2004 - February 2007.
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At 6 weeks 571 (82%) of the babies returned for HIV testing by 
PCR, and 16 (2.8%, 95% confidence interval (CI) 1.7 - 4.6%) were 
found to be HIV positive. Bivariate analysis found no statistically 
significant association between potential maternal risk factors 
(including age, marital status, gestation at first visit, CD4 counts and 
delivery method) and loss to follow-up at 6 weeks. Of the 694 HIV-
positive women with live births, 524 (76%) were lost to follow-up 3 
months after delivery. After 6 months, of 700 women who delivered 
only 150 (21%) were receiving ongoing care at the McCord Hospital 
general HIV clinic, including only 54 (37%) of the 146 women who 
were initially eligible for HAART for life (Fig. 1). 
Discussion
We examined a PMTCT programme in a high HIV prevalence setting 
in sub-Saharan Africa, which used dual and triple therapy and opt-out 
testing. Of the women presenting for antenatal care, 92% were tested for 
HIV and overall HIV transmission occurred in less than 3% of babies 
tested 6 weeks after delivery. This is in sharp contrast to transmission 
rates in KZN public sector clinics at the time, where an estimated 
20.8% (95% CI 18.2 - 23.6) of 6-week-old infants born to HIV-positive 
pregnant women, where only single-dose nevirapine was utilised, 
were found to be infected.13 Of HAART-eligible women, 84% were 
commenced on HAART, compared with only 51% in a 2010 study from 
Cape Town.14 However, of those women identified as HIV positive, 
only 21% were attending the general HIV clinic 6 months later. At 
McCord Hospital, access (financial and geographical) and the stigma of 
follow-up at the ‘HIV clinic’ may in part have been responsible for this 
drop-off. Longer-term follow-up is important to encourage mothers 
to engage with services and stay healthy and adherent to medication, 
thereby improving their own and their infants’ chances of survival. This 
is recognised as a challenge to PMTCT providers.15
Table II. Characteristics and outcomes of 703 HIV-positive women attending the McCord antenatal clinic by maternal regimen 
administered, Durban, 1 March 2004 - 28 February 2007
Maternal regimen
Characteristics and outcome
No drug given 
(N (%))
Single-dose 
nevirapine  
(N (%))
Dual therapy† 
(N (%))
Triple therapy‡ 
(N (%))
No record  
(N (%)) Total (N (%))
All HIV-positive women 19 (2.7) 135 (19.2) 94 (13.4) 424 (60.3) 31 (4.4) 703 (100)
Year treated
   Year 1 8 (3.9) 67 (32.2) 48 (23.1) 82 (39.4) 3 (1.4) 208
   Year 2 5 (2.3) 39 (17.7) 18 (8.2) 145 (65.9) 13 (5.9) 220
   Year 3 6 (2.2) 29 (10.5) 28 (10.2) 197 (71.6) 15 (5.5) 275
CD4 count (cells/µl)
   <200 5 (3.4) 11 (7.5) 1 (0.7) 122 (83.6) 7 (4.8) 146
   ≥200 6 (1.2) 80 (16.1) 90 (18.2) 297 (59.9) 23 (4.6) 496
  Unknown 8 (13.1) 44 (72.1) 3 (4.9) 5 (8.2) 1 (1.6) 61
Pregnancy outcomes
   Vaginal delivery 11 (4.5) 30 (12.1) 33 (13.4) 168 (68.0) 5 (2.0) 247
   Caesarean section 8 (1.9) 104 (24.3) 61 (14.3) 251 (58.8) 3 (0.7) 427
   Intra-uterine death 0 0 0 1 5 6
   Miscarriage 0 0 0 0 2 2
   Mother/fetus died 0 0 0 0 1 1
   Delivery method unknown 0 1 0 4 15 20
All live babies* 19 135 95 427 23 699 (100)
Baby 6-week PCR
   Positive 0 7 1 8 0 16 (2.3)
   Negative 7 94 84 365 5 555 (79.4)
   Unknown 12 34 10 54 18 128 (18.3)
HIV transmission
   Positive babies/live babies tested 0/7 7/101 1/85 8/373 0/5 16/571
(0%) (6.9%) (1.2%) (2.1%) (0%) (2.8%)
*6 sets of twins, so 709 fetuses but 10 died or miscarried (including 1 pair twins), resulting in 699 live births.
†Dual therapy, zidovudine during pregnancy and nevirapine at delivery.
‡Triple-therapy regimens in Table III.
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The retrospective nature of the study may have led to information 
and selection bias. Specifically, the 18% loss to follow-up of babies 6 
weeks after delivery may have led us to underestimate transmission. 
Although unlikely, if all 128 infants who did not return at 6 weeks were 
infected, transmission may have been as high as 20.6% (95% CI 17.6 - 
23.6). Poor retention following delivery also compromised our ability 
to accurately determine the HIV transmission to infants by 6 months of 
age and to assess other maternal and child health outcomes. 
Because of the user fee, patients attending McCord Hospital are 
likely to be socio-economically and educationally better off than 
those attending public facilities. This may influence general health 
and adherence to medication and results may therefore not be 
generalisable to the broad antenatal population of South Africa, 
limiting the external validity of the study.
Triple therapy for PMTCT is feasible in the sub-Saharan setting, 
but implementation requires sufficient resources for staff, their 
training, and the availability of basic laboratory technology and 
drugs. A goal of the South African National Strategic Plan for HIV/
AIDS and Sexually Transmitted Infections 2007 - 201116 is to reduce 
MTCT of HIV to less than 5%. Results of operational research at sites 
using dual therapy suggest that it is unlikely that vertical transmission 
of less than 5 - 9% will be achieved.17,18 This study demonstrates 
that the appropriate use of available resources can achieve good 
outcomes; in particular, the use of CD4 counts and viral loads in this 
programme allowed tailored prophylactic regimens and a reduced 
caesarean section rate. Focusing solely on short-term MTCT of HIV, 
however, is insufficient and results in lost opportunities. Outcomes 
such as 6-month and 1-year HIV-free infant survival should become 
standard indicators. The importance of longer-term follow-up must 
be emphasised, and successful strategies to link women to ongoing 
care are crucial to sustain the gains of PMTCT programmes. 
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Table III. Triple therapy prescribed to 424 HIV-positive women attending the McCord antenatal clinic, Durban, 1 March 2004 - 28 
February 2007
Triple therapy regimen N % Rationale
AZT, 3TC & NVP 89 21.0 Standard treatment for those with CD4 <200 cells/µl before 2005
AZT, 3TC & efavirenz 34 8.0 Standard treatment for those with CD4 >200, VL 1 500 copies/ml and after 1st 
trimester, before donor funding available. Also used in patients on TB treatment 
or where NVP or Kaletra contraindicated
d4T, 3TC & NVP 83 19.6 Standard regimen for patients coming from/continuing in DOH settings, as first 
line when CD4 <200
AZT, 3TC & lopinavir/ritonavir 187 44.1 Standard regimen used for patients with CD4 >200 and VL >1 500 copies/ml after 
donor funding available in 2005
d4T, 3TC & efavirenz 18 4.3 Patients already on HAART for life (CD4 <200) who later became pregnant, 
or those started after 23 weeks’ gestation on concurrent TB treatment, or with 
toxicities to NVP
AZT, 3TC & nelfinavir 2 0.5 Used for the same indications as Kaletra, but only if patients were initiated on this 
prior to booking at McCord and could afford it
AZT, ddI, lopinavir/ritonavir 1 0.2 Long-term HAART patients who were switched to this regimen due to evidence of 
resistance. ddI usually avoided
3TC, d4T & lopinavir/ritonavir 10 2.3 Used in patients who needed HAART for life (CD4 <200) but where NNRTIs 
contraindicated
    Total 424 100
VL = viral load; AZT = zidovudine; 3TC = lamivudine; d4T = stavudine; NVP = nevirapine; ddI = didanosine; NNRTI = non-nucleoside reverse transcriptase inhibitor; DOH = KwaZulu-Natal 
Department of Health; TB = tuberculosis.
